166 related articles for article (PubMed ID: 24503901)
1. Proteome analysis for downstream targets of oncogenic KRAS--the potential participation of CLIC4 in carcinogenesis in the lung.
Okudela K; Katayama A; Woo T; Mitsui H; Suzuki T; Tateishi Y; Umeda S; Tajiri M; Masuda M; Nagahara N; Kitamura H; Ohashi K
PLoS One; 2014; 9(2):e87193. PubMed ID: 24503901
[TBL] [Abstract][Full Text] [Related]
2. Label-free quantitative proteomics and N-glycoproteomics analysis of KRAS-activated human bronchial epithelial cells.
Sudhir PR; Chen CH; Pavana Kumari M; Wang MJ; Tsou CC; Sung TY; Chen JY; Chen CH
Mol Cell Proteomics; 2012 Oct; 11(10):901-15. PubMed ID: 22761399
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS: potential involvement of miR-31 in lung carcinogenesis.
Okudela K; Suzuki T; Umeda S; Tateishi Y; Mitsui H; Miyagi Y; Ohashi K
Oncol Rep; 2014 Oct; 32(4):1374-84. PubMed ID: 25050641
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
5. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of DUSP6 expression in lung cancer: its mechanism and potential role in carcinogenesis.
Okudela K; Yazawa T; Woo T; Sakaeda M; Ishii J; Mitsui H; Shimoyamada H; Sato H; Tajiri M; Ogawa N; Masuda M; Takahashi T; Sugimura H; Kitamura H
Am J Pathol; 2009 Aug; 175(2):867-81. PubMed ID: 19608870
[TBL] [Abstract][Full Text] [Related]
7. CLIC4/Arf6 Pathway.
Abdul-Salam VB; Russomanno G; Chien-Nien C; Mahomed AS; Yates LA; Wilkins MR; Zhao L; Gierula M; Dubois O; Schaeper U; Endruschat J; Wojciak-Stothard B
Circ Res; 2019 Jan; 124(1):52-65. PubMed ID: 30582444
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
9. Up-Regulation of S100A11 in Lung Adenocarcinoma - Its Potential Relationship with Cancer Progression.
Woo T; Okudela K; Mitsui H; Tajiri M; Rino Y; Ohashi K; Masuda M
PLoS One; 2015; 10(11):e0142642. PubMed ID: 26544866
[TBL] [Abstract][Full Text] [Related]
10. Reciprocal modifications of CLIC4 in tumor epithelium and stroma mark malignant progression of multiple human cancers.
Suh KS; Crutchley JM; Koochek A; Ryscavage A; Bhat K; Tanaka T; Oshima A; Fitzgerald P; Yuspa SH
Clin Cancer Res; 2007 Jan; 13(1):121-31. PubMed ID: 17200346
[TBL] [Abstract][Full Text] [Related]
11. Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas.
Bjaanaes MM; Halvorsen AR; Solberg S; Jørgensen L; Dragani TA; Galvan A; Colombo F; Anderlini M; Pastorino U; Kure E; Børresen-Dale AL; Brustugun OT; Helland A
Int J Cancer; 2014 Oct; 135(8):1812-21. PubMed ID: 24599520
[TBL] [Abstract][Full Text] [Related]
12. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
13. Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas.
McCleland ML; Adler AS; Deming L; Cosino E; Lee L; Blackwood EM; Solon M; Tao J; Li L; Shames D; Jackson E; Forrest WF; Firestein R
Clin Cancer Res; 2013 Feb; 19(4):773-84. PubMed ID: 23224736
[TBL] [Abstract][Full Text] [Related]
14. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
Vandal G; Geiling B; Dankort D
PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
[TBL] [Abstract][Full Text] [Related]
15. Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation.
Ichinokawa H; Ishii G; Nagai K; Kawase A; Yoshida J; Nishimura M; Hishida T; Ogasawara N; Tsuchihara K; Ochiai A
Hum Pathol; 2013 Dec; 44(12):2636-42. PubMed ID: 24119562
[TBL] [Abstract][Full Text] [Related]
16. Significant association between EGFR-mutated lung adenocarcinoma and past illness from gastric cancer or uterine myoma: its implication in carcinogenesis.
Okudela K; Woo T; Yazawa T; Ogawa N; Tajiri M; Masuda M; Kitamura H
Lung Cancer; 2009 Dec; 66(3):287-91. PubMed ID: 19362747
[TBL] [Abstract][Full Text] [Related]
17. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.
Vicent S; Chen R; Sayles LC; Lin C; Walker RG; Gillespie AK; Subramanian A; Hinkle G; Yang X; Saif S; Root DE; Huff V; Hahn WC; Sweet-Cordero EA
J Clin Invest; 2010 Nov; 120(11):3940-52. PubMed ID: 20972333
[TBL] [Abstract][Full Text] [Related]
19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
20. Assessment of MAGE-A expression in resected non-small cell lung cancer in relation to clinicopathologic features and mutational status of EGFR and KRAS.
Ayyoub M; Memeo L; Alvarez-Fernández E; Colarossi C; Costanzo R; Aiello E; Martinetti D; Valmori D
Cancer Immunol Res; 2014 Oct; 2(10):943-8. PubMed ID: 24866168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
